A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

Idiopathic Retroperitoneal Fibrosis Clinical Trial

Official title:
A Prospective, Controlled, Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

Status Recruiting

Clinical Trial Summary

This is a prospective study to investigate the treatment response of Tocilizumab on patients with idiopathic retroperitoneal fibrosis（IRPF）. Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled. The IRPF patients will accept Tocilizumab or Glucocorticoid monotherapy for 3 months. Endpoints: The primary endpoint is to investigate the response of Tocilizumab on IRPF patients; the secondary endpoints include the decrease of inflammatory markers, side effect.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Fibrosis
Idiopathic Retroperitoneal Fibrosis
Retroperitoneal Fibrosis

Clinical Trial Details

NCT number	NCT04762784
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact
Status	Recruiting
Phase	Phase 4
Start date	July 1, 2020
Completion date	February 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05428826` - Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis	Phase 4
Recruiting	`NCT01240850` - Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial	Phase 3
Recruiting	`NCT04314323` - National Registry of IRPF in China
Recruiting	`NCT04762810` - A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis	Phase 4
Recruiting	`NCT04312854` - A Prospective Cohort Study of IRPF in China